Aurora Cannabis renews exclusive supply deal with Luxembourg

Aurora Cannabis renews exclusive supply deal with Luxembourg

The company has secured an extension through its Aurora Deutschland subsidiary

Aurora Cannabis (TSE: ACB) and the Luxembourg Health Ministry have agreed to keep their relationship going. The global cannabis company announced yesterday that its wholly-owned Aurora Deutschland subsidiary has been chosen, through a public bidding process, by Luxembourg to be the exclusive supplier of a second delivery of medical cannabis to the European country.

According to the terms of the bid award, Aurora’s subsidiary will provide medical cannabis to the Luxembourg Division de la Pharmacie et des Medicaments (Pharmacy and Medication Division). It is the second time Aurora Deutschland has been given the award by the country and, despite the amount of the supply being small, shows Luxembourg’s faith in the company.

Aurora Deutschland’s chief global business development officer, Neil Belot, states, “We are proud to continue serving as the exclusive supplier of medical cannabis to the Luxembourg Health Ministry. Adding to the many achievements of our European team, which also includes our recent selection as one of only three companies to establish domestic production in Germany, our expanded supply agreement with Luxembourg reinforces Aurora’s ability to act as a trusted partner that can readily meet the complex needs of diverse international markets.”

The associate director of Aurora’s EU Business Development division, Maximilian Weinberg, added, “As the established market leader across Europe, Aurora is exceptionally well positioned to leverage our significant early mover advantage to accommodate the growth of new medical cannabis markets as opportunities arise. We’re proud of our teams’ achievements to date and look forward to supplying patients in Luxembourg with improved access to high-quality medical cannabis.”

Aurora is one of the most globally diverse cannabis companies. It has seen rapid organic growth and strong execution on strategic M&A, which now includes 16 wholly-owned subsidiaries. These include MedReleaf, CanvasRX, Peloton Pharmaceutical, Aurora Deutschland, H2 Biopharma, Urban Cultivator, BC Northern Lights, Larssen Greenhouses, CanniMed Therapeutics, Anandia, HotHouse Consulting, MED Colombia, Agropro, Borela, ICC Labs and Whistler.